19,22
21-февраля-25 16:45:00
15 мин. задержка
Акции
+0,22
+1,16%
Сегодняшний диапазон
18,05 - 19,64
ISIN
N/A
Источник
NASDAQ
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
10 фев 2025 08:00:00 Источник Nasdaq GlobeNewswire
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
10 янв 2025 08:00:00 Источник Nasdaq GlobeNewswire
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
08 янв 2025 08:00:01 Источник Nasdaq GlobeNewswire